Treatment of Invasively Ventilated Adults With Early Activity and Mobilisation
Launched by AUSTRALIAN AND NEW ZEALAND INTENSIVE CARE RESEARCH CENTRE · Apr 25, 2017
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
The TEAM Trial is a definitive phase III multi-centre randomised controlled trial in mechanically ventilated patients. Supported by compelling preliminary data, the trial will determine whether early activity and mobilisation during mechanical ventilation improves days alive and at home at 6 months compared to standard care. Recruiting 750 patients, this will be the largest trial ever conducted of early mobilisation.
Patients allocated to the early activity and mobilisation protocol (intervention group) will be assessed by a physiotherapist daily during the ICU stay to determine the highes...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 18 years or older.
- • 2. Intubated and expected to remain invasively mechanically ventilated the day after tomorrow.
- 3. Sufficient cardiovascular stability to make mobilisation potentially possible, as indicated by:
- • 1. the absence of current brady-arrhythmia requiring pharmacological support
- • 2. a current ventricular rate ≤ 150 bpm
- • 3. most recent lactate ≤ 4.0 mmol/L
- • 4. current combined noradrenaline/adrenaline infusion rate of ≤ 0.2 mcg/kg/min, OR if noradrenaline/adrenaline infusion rate has increased by more than 25% in the last 6 hours, dose must be \<0.1 mcg/kg/min.
- • 5. most recent cardiac index ≥ 2.0 L/min/m2 (where measured)
- • 6. no current requirement for VA ECMO
- 4. Sufficient respiratory stability to make mobilisation potentially possible, as indicated by:
- • 1. current FiO2 ≤ 0.6
- • 2. current PEEP ≤ 16 cm H20
- • 3. an absence of current requirement for NO, prone ventilation, neuromuscular blockers, ventilation, prostacyclin, VV ECMO or HFOV
- • 4. current RR ≤ 45 bpm
- Exclusion Criteria:
- • 1. Dependent for activities of daily living in the month prior to current ICU admission (gait aids are acceptable).
- • 2. Documented cognitive impairment.
- • 3. Proven or suspected acute primary brain pathology (e.g. traumatic brain injury, stroke, hypoxic brain injury).
- • 4. Proven or suspected spinal cord injury or other neuromuscular disease that will result in permanent or prolonged weakness (not including ICU acquired weakness).
- • 5. Has rest in bed orders and/or has bilateral non-weight bearing orders for the lower limbs.
- • 6. Life expectancy less than 180 days due to a chronic or underlying medical condition.
- • 7. Death is deemed inevitable as a result of the current illness and either the patient or treating clinical or substitute decision maker are not committed to full active treatment.
- • 8. Unable to communicate in the official local language.
- • 9. This is not the first ICU admission in the index hospital admission.
- • 10. Fulfilled all inclusion criteria and none of the exclusion criteria ≥ 72 hours
About Australian And New Zealand Intensive Care Research Centre
The Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) is a leading research organization dedicated to improving outcomes in critically ill patients through innovative clinical trials and research initiatives. Based at Monash University, the Centre fosters collaborative partnerships among clinicians, researchers, and institutions across Australia and New Zealand. Its focus on evidence-based practice and translational research aims to enhance the quality of intensive care, drive advancements in treatment protocols, and ultimately improve patient care in the intensive care unit (ICU) setting. ANZIC-RC is committed to addressing key challenges in critical care medicine, ensuring that findings from its trials contribute to better health outcomes and inform clinical guidelines globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Adelaide, South Australia, Australia
Leipzig, , Germany
Camperdown, New South Wales, Australia
Woolloongabba, Queensland, Australia
Nedlands, Western Australia, Australia
Sydney, New South Wales, Australia
Wollongong, New South Wales, Australia
Hamilton, , New Zealand
Brisbane, Queensland, Australia
Melbourne, Victoria, Australia
Perth, Western Australia, Australia
Launceston, Tasmania, Australia
Tauranga, , New Zealand
Wellington, , New Zealand
Bristol, , United Kingdom
Nottingham, , United Kingdom
Toowoomba, Queensland, Australia
Reading, , United Kingdom
Truro, , United Kingdom
Sydney, New South Wales, Australia
Swansea, , United Kingdom
Dublin, , Ireland
Prahran, Victoria, Australia
Melbourne, , Australia
Melbourne, Victoria, Australia
Dublin, , Ireland
Frimley, , United Kingdom
Auckland, , New Zealand
Auckland, , New Zealand
Redcliffe, Queensland, Australia
Lewisham, , United Kingdom
Perth, Western Australia, Australia
Subiaco, Western Australia, Australia
Sydney, New South Wales, Australia
Birtinya, Queensland, Australia
Brisbane, Queensland, Australia
Caboolture, Queensland, Australia
Chermside West, Queensland, Australia
Rockhampton, Queensland, Australia
Geelong, Victoria, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Berlin, , Germany
Munich, , Germany
Galway, , Ireland
Tallaght, , Ireland
Woolwich, , United Kingdom
Patients applied
Trial Officials
Carol Hodgson, Prof
Study Chair
ANZIC-RC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials